The use of weight-loss jabs may be associated with wider health benefits including lower risk of stroke and dementia, a study ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like Ozempic and Wegovy, provide significant neurological and behavioral health ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Millions of obese Americans have achieved successful weight loss through use of glucagon-like peptide-1 agonists (GLP-1), a game-changing class of obesity medications. Results are often dramatic, but ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

Weight-loss medicines such as Ozempic might raise a person’s likelihood of developing conditions including arthritis.